Applied Therapeutics, Inc. - Common Stock (APLT)
Frequently Asked Questions About Applied Therapeutics, Inc. - Common Stock (APLT)
Has Applied Therapeutics, Inc. conducted clinical trials?
Yes, Applied Therapeutics has conducted multiple clinical trials to evaluate the safety and efficacy of its product candidates. The company actively engages in these trials to gather data and insights on their drugs, which are crucial for regulatory approval and future commercialization.
How can investors learn more about Applied Therapeutics?
Investors can learn more about Applied Therapeutics by visiting the company's official website, reviewing its investor relations section, and accessing financial reports, press releases, and announcements. Additionally, investors can follow the company on various social media platforms for real-time updates and insights into its developments.
How does Applied Therapeutics ensure regulatory compliance?
Applied Therapeutics is committed to maintaining stringent regulatory compliance throughout its drug development process. The company works closely with regulatory agencies, including the FDA, to adhere to guidelines and standards, ensuring the safety and efficacy of its therapies while achieving timely approvals.
Is Applied Therapeutics involved in any corporate social responsibility initiatives?
Yes, Applied Therapeutics is dedicated to corporate social responsibility by actively engaging in community outreach, supporting health awareness programs, and committing to ethical and sustainable business practices. The company believes in giving back and contributing positively to society while advancing healthcare innovations.
Is Applied Therapeutics involved in any partnerships?
Yes, Applied Therapeutics actively seeks partnerships with other companies, research institutions, and academic organizations to enhance its development capabilities and expand its therapeutic offerings. Collaborations often focus on areas such as clinical trial execution, research advancement, and technology sharing.
What are the primary challenges faced by Applied Therapeutics?
Like many biotechnology companies, Applied Therapeutics faces several challenges, including navigating the complexities of clinical trials, securing funding for research and development, and achieving regulatory approval for its therapeutic candidates. Additionally, staying competitive in a rapidly evolving industry landscape poses ongoing hurdles.
What does Applied Therapeutics, Inc. do?
Applied Therapeutics, Inc. is a biotechnology company focused on developing and commercializing innovative medicines for diseases with significant unmet medical needs. The company’s primary focus is on metabolic diseases, including those associated with imbalances in cellular metabolism, leveraging its proprietary technology platforms to develop therapeutic candidates that address these conditions.
What is Applied Therapeutics, Inc.'s ticker symbol?
Applied Therapeutics, Inc. is publicly traded on the Nasdaq under the ticker symbol 'APLT'. This allows investors to buy and sell shares of the company on the stock exchange, reflecting its performance and growth in the biotechnology sector.
What is the company's lead product candidate?
The company's lead product candidate is AT-001, which is being developed to treat patients with Alzheimer's disease-related dementia. This treatment aims to address the glucocerebrosidase deficiency that contributes to cognitive decline, and preliminary clinical trials have shown promise in improving patient outcomes.
What is the company’s approach to innovation?
Applied Therapeutics adopts a patient-centric approach in its innovation strategy, focusing on understanding the specific needs of patients with unmet medical needs. This drive for innovation is complemented by a commitment to scientific excellence, enabling the development of therapies that can truly transform care in challenging medical conditions.
What is the company’s vision for the future?
Applied Therapeutics envisions a future where its innovative therapies significantly improve treatment outcomes for patients with complex metabolic diseases. The company aims to expand its pipeline and bring multiple products to market, establishing itself as a leader in the biotechnology landscape while positively impacting patient lives.
What is the goal of the company’s research and development?
The goal of Applied Therapeutics' research and development efforts is to create transformative therapies that significantly improve the lives of patients suffering from rare and chronic diseases. The company aims to deliver innovative solutions that address the underlying causes of these conditions, offering new hope where existing treatments may be lacking.
What is the significance of orphan drug designation?
Orphan drug designation provides important incentives for the development of treatments for rare diseases, including market exclusivity, tax credits, and assistance with clinical trial design. For Applied Therapeutics, receiving this designation for its product candidates underscores the company’s commitment to addressing unmet medical needs in underserved patient populations.
What recent milestones has Applied Therapeutics achieved?
Recently, Applied Therapeutics has achieved notable milestones, including the successful completion of clinical trials for its lead product candidate AT-001 and receiving orphan drug designation for some of its therapeutic targets. These achievements mark significant progress in the company's goals and highlight its potential for commercialization.
What should potential investors consider about Applied Therapeutics?
Potential investors should consider Applied Therapeutics' innovative approach to drug development, its promising pipeline, and the experienced leadership team. It is essential to evaluate the company's financial health, market potential, and the competitive landscape within the biotechnology sector before making any investment decisions.
What therapeutic areas does Applied Therapeutics focus on?
Applied Therapeutics primarily focuses on metabolic diseases, with a particular emphasis on conditions associated with cellular metabolism dysfunction. The company is actively developing therapies for diseases such as diabetic complications, metabolic disorders, and neurodegenerative diseases.
When was Applied Therapeutics, Inc. founded?
Applied Therapeutics, Inc. was founded in 2016. Since its inception, the company has built a strong pipeline of drug candidates and has positioned itself as a leader in developing innovative therapies targeting rare and chronic metabolic diseases.
Where is Applied Therapeutics, Inc. headquartered?
Applied Therapeutics, Inc. is headquartered in New York City, New York. This strategic location allows the company to foster collaboration with leading research institutions and attract talent in the vibrant biotech and pharmaceutical sectors surrounding the city.
Who are the key executives at Applied Therapeutics?
Key executives at Applied Therapeutics include the company's founder and CEO, Dr. Shoshana Shendelman, who has extensive experience in drug development and biotechnology. The executive team is complemented by professionals with deep backgrounds in finance, clinical development, regulatory affairs, and strategic operations to propel the company forward.
What is the current price of Applied Therapeutics, Inc. - Common Stock?
The current price of Applied Therapeutics, Inc. - Common Stock is 0.4257
When was Applied Therapeutics, Inc. - Common Stock last traded?
The last trade of Applied Therapeutics, Inc. - Common Stock was at 3:26 pm EDT on April 3rd, 2025
What is the market capitalization of Applied Therapeutics, Inc. - Common Stock?
The market capitalization of Applied Therapeutics, Inc. - Common Stock is 48.89M
How many shares of Applied Therapeutics, Inc. - Common Stock are outstanding?
Applied Therapeutics, Inc. - Common Stock has 114.85M shares outstanding.